OLO. The first complete blood count device for point-of-care
Blood diagnostics, meet machine vision
Combining patented sample preparation with machine-vision detection, OLO delivers unprecedented diagnostic accuracy, simplicity and reliability.
Simple from the start
Ready in seconds
The manual staining workflow has been replaced by a self-contained unit that is sample-ready in seconds. Just two drops of blood is all it takes. Patented technology is used to form a standardized monolayer of cells.
Once inserted into the instrument, the sample is rapidly imaged using a specialized multi-channel microscope. The extraordinary accuracy of the images allows Sight’s algorithms to carefully differentiate cells as well as identify various anomalies.
The scanned images are analyzed using machine vision and AI techniques.
Sight’s advanced algorithm, first deployed in 2012 to detect malaria ,has been field proven in more than 24 countries.
Lab-quality results, without the lab
Sight’s algorithm analyzes characteristics like cell size, shape, and intracellular morphology. Lab-quality results are delivered in minutes, displayed on-screen and available for printout and mail.
Company growth trajectory
The story of OLO began in 2015, with the application of Sight’s digital fluorescent microscopy and advanced computer vision algorithms to revolutionize how Complete Blood Count (CBC) tests are done in the world.
This innovation has since received FDA 510(k) clearance for use in moderate complexity laboratories in the United States.
Outside of the United States, OLO has the CE Mark according to the IVD European directive in point of care settings.
OLO, together with Parasight, OLO’s predecessor that diagnoses malaria based on the same breakthrough technology, extend Sight’s commercial footprint and impact across 5 continents.
Learn more about how you can help Sight take the next step toward transforming health systems and patient outcomes globally.